Nutriband Announces Patent Issued for its Transdermal Abuse Deterrent Technology
Nutriband Inc. recently announced the United States Patent and Trademark Office (USPTO) issued patent number 12,318,492 on June 3, 2025, entitled Abuse and Misuse Deterrent Transdermal Systems.
The issuance of this patent further expands Nutriband’s intellectual property protection in the United States for its portfolio of abuse deterrent transdermal products based on its proprietary Aversa™ abuse deterrent technology. This technology can be incorporated into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential.
The AVERSA abuse deterrent technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries, including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
Nutriband’s lead product under development is Aversa Fentanyl, an abuse deterrent fentanyl transdermal system, with the potential to become the first abuse deterrent pain patch on the market with peak annual US sales estimated to be$80 million to $200 million.
Nutriband’s AVERSA abuse deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. For more information, visit www.nutriband.com.
Total Page Views: 214
